Analysis on the efficacy and safety of ruxolitinib combined with umbilical cord-mesenchymal stem cells in the treatment of refractory severe gastrointestinal acute graft-versus-host disease
10.3760/cma.j.cn101480-20210219-00010
- VernacularTitle:芦可替尼联合脐带间充质干细胞治疗难治性重度肠道急性移植物抗宿主病的疗效及安全性分析
- Author:
Yue MA
1
;
Zhe YU
1
;
Xin LI
1
;
Tianjie HAN
1
;
Lijun LI
1
;
Lu LU
1
Author Information
1. 山东大学附属山东省立第三医院血液科，济南 250031
- Publication Type:Journal Article
- Keywords:
Gastrointestinal acute graft-versus-host-disease;
Stem cell transplantation;
Ruxolitinib;
Mesenchymal stem cells;
Umbilical cord;
Reg3α protein
- From:
Chinese Journal of Inflammatory Bowel Diseases
2022;06(2):133-137
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of ruxolitinib combined with umbilical cord-mesenchymal stem cells (UC-MSC) in the treatment of patients with refractory severe gastrointestinal acute graft-versus-host disease (GI-aGVHD) .Methods:Clinical data of four patients with refractory severe GI-aGVHD who were treated with ruxolitinib (5 mg twice daily) combined with UC-MSC (once a week, 5×10 6/kg) in addition to the original immunosuppressant in Shandong Provinical Third Hospital of Shandong University from March 2018 to January 2020 were collected. Infusion of UC-MSC was stopped, and ruxolitinib was reduced gradually and even stopped according to the clinical symptoms and the reg3α level. The baseline information, clinical efficacy and adverse reactions were summarized and analyzed descriptively. Results:Four patients achieved complete remission with a median time of 12 (10-14) days. Intestinal mucosal congestion and edema were relieved and the protein level of Reg3α continued to decrease to normal. After the withdrawal of immunosuppressant and ruxolitinib, the condition was stable and intestinal symptoms were not repeated. One patient died of Pneumocystis pneumonia when the oral dose of ruxolitinib was reduced to 5 mg/d. The other three patients survived. Conclusion:Ruxolitinib combined with UC-MSC is an effective method for the refractory severe GI-aGVHD and has less adverse reactions.
